July 16, 2013
The government has rejected calls for people in England who suffer from long-term conditions (LTCs) to be eligible for free prescriptions.
Astellas/WG Consulting and Durham Dales CCG take gold in the Partnerships in Health Awards
Things are not looking good for Pfizer's Bosulif on the NHS, after cost regulators said they were minded not to approve its use in patients with a certain form of leukaemia.
England is in danger of losing 16,000 GPs by 2021 because of the "black hole" in NHS funding, the Royal College of General Practitioners is warning.
July 11, 2013
The NHS is looking at a funding gap of £30bn in the next eight years
The National Institute for Health and Care Excellence (NICE) has issued new draft guidance not recommending Celgene's Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes (MDS), but has also opened a public consultation on this preliminary decision.
SMC yes for Humira, but it's a 'no' for Afinitor and Zaltrap.
July 09, 2013
The Department of Health has announced the birth of Genomics England - a state-owned company charged with overseeing the mapping of National Health Service patients' DNA.
A complete overhaul of the NHS' operating model is needed in order to deliver better patient outcomes and care at lower costs, and key to this transformation will be partnerships with the life sciences sector, says a new report.
Patients with advanced breast cancer living in England and Wales will not be allowed routine access to Novartis' Afinitor on the National Health Service, following a decision from the National Institute for Health and Care Excellence that has angered the company and charities.
Is your pharma firm fit to communicate digitally?
PharmaTimes 2013 Copyright | RSS Feed Subscriptions Software Development by DCSL Software